Is Gilead Sciences (NASDAQ:GILD) undervalued? Top hedge fund, SAC Capital Advisors, adds $177 million position. Clinical trial on new drug was poorly received, sending the stock down 20%. Tweaker thinks valuation is on target. Is now the time to buy?
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.